Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325

Jennifer S. Carew, Steffan T. Nawrocki

Research output: Contribution to journalComment/debatepeer-review

24 Scopus citations


Although macroautophagy/autophagy is a key contributor to malignant pathogenesis and therapeutic resistance, there are few FDA-approved agents that significantly affect this pathway. We used medicinal chemistry strategies to develop ROC-325, an orally available novel inhibitor of lysosomal-mediated autophagy. Detailed in vitro and in vivo studies in preclinical models of renal cell carcinoma demonstrated that ROC-325 triggered the hallmark features of lysosomal autophagy inhibition, was very well tolerated, and exhibited significant superiority with respect to autophagy inhibition and anticancer activity over hydroxychloroquine. Our findings support the clinical investigation of the safety and preliminary efficacy of ROC-325 in patients with autophagy-dependent malignancies and other disorders where aberrant autophagy contributes to disease pathogenesis.

Original languageEnglish (US)
Pages (from-to)765-766
Number of pages2
Issue number4
StatePublished - Apr 3 2017


  • ROC-325
  • autophagy inhibitor
  • hydroxychloroquine
  • lucanthone
  • renal cell carcinoma

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325'. Together they form a unique fingerprint.

Cite this